Theratech and Proctor and Gamble partner in $35 million hormone replacement therapy deal:
This article was originally published in Clinica
Executive Summary
Procter & Gamble and Theratech are to develop a combined transdermal testosterone and estradiol/testosterone hormone replacement therapy patch for women. P&G will fund the project and provide milestone payments up to $35 million to Theratech. P&G will retain marketing rights except in Asia, although certain Asian countries may be included in the deal. The testosterone patch is in Phase II trials.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.